These findings indicate that NRXN1 knockdown induces EMT and invasion via GSK3β activation and identifies GSK3β inhibitors as potential therapeutic candidates for NRXN1 downregulation in colon cancer. The gene discussed is NRXN1; the disease is colonic neoplasm.